The global plasma fractionation market was valued at approximately US$ 32.75 billion in 2023 and is expected to expand to US$ 72.86 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034. This growth is driven by an increasing demand for plasma-derived medicines, which are used to treat conditions such as rabies, tetanus, shock, and trauma. As a result, the plasma fractionation market is experiencing significant growth worldwide.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5304
Plasma fractionation is a complex separation process that extracts various protein components from human blood plasma. This procedure plays a crucial role in pharmaceutical research and in the development of advanced fractionation technologies. Plasma, a key component of human blood, is composed of water (91.5%), proteins (7%), and salts (1.5%). The protein content includes essential proteins such as albumin (54%), immunoglobulin (38%), and fibrinogen (7%).
This process is vital in the production of medicines that are used to treat various diseases, including immunodeficiencies, genetic disorders, rabies, tetanus, shock, and trauma. As the prevalence of these global health conditions continues to rise, the demand for plasma-derived medicines has surged, driving the expansion of the plasma fractionation market.
The scope of plasma fractionation has greatly expanded in recent years, particularly in the healthcare industry and the development of therapeutics and biologics. Currently, over 20 different proteins derived from plasma are being utilized in medical treatments. The growing demand for high-quality plasma-based therapies has led manufacturing companies to scale up production to meet the rising need.
Several factors are fueling the rapid growth of the plasma fractionation market, including the increasing demand for plasma-derived medicines, advancements in fractionation technologies, and the growing recognition of the importance of blood donations, especially in developing countries.
The plasma fractionation market has witnessed significant investments and innovations over the past year. For instance:
Several factors contribute to the robust growth of the plasma fractionation market:
Artificial intelligence (AI) and automation are poised to revolutionize the plasma fractionation process. By integrating AI into fractionation workflows, companies can streamline operations, reduce human error, and lower operational costs. The ability to automate various stages of the fractionation process also enhances efficiency, accuracy, and consistency.
AI can also aid in overcoming some of the challenges associated with plasma fractionation. For instance, isolating specific plasma components can be a difficult and time-consuming task using traditional methods. With AI-powered technologies, this process can be simplified, resulting in more effective fractionation.
Additionally, AI can assist in the long-term storage of plasma components. Automated storage systems powered by AI can maintain the integrity of plasma components, ensuring they remain usable for extended periods, which is essential for therapeutic applications.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-fraction-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5304
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The global digital health market is witnessing a steady rise and much of it is driven by the increasing number… Read More
In 2025, North America emerged as the clear frontrunner in the healthcare Contract Research Organization (CRO) market and it’s easy… Read More
Powering the Future of Cell and Gene Therapy Virocell Biologics, a leading name in vector manufacturing for cell and gene… Read More
A Big Leap Forward in PAH Care Pahr Therapeutics Inc. has raised $14 million in seed funding to accelerate its… Read More
Reimagining Immunology, Together In a groundbreaking partnership, Bristol Myers Squibb (BMS) and Bain Capital have come together to launch a… Read More
Genethon, a global leader in gene therapy for rare genetic diseases, has received the green light from the UK and… Read More